BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Nov. 18, 2003
View Archived Issues
GenPath, Merck Sign Potential $100M Deal For Cancer Drugs
Less than a month after raising $42.7 million in a Series B round, GenPath Pharmaceuticals Inc. said it has nailed down a multiyear cancer deal with Merck & Co. Inc. worth up to $100 million, excluding royalties. (BioWorld Today)
Read More
Allos Presents RSR13 Data; NDA Completion Expected This Year
Read More
Anadys Files $86.25M IPO; HCV Drug Duo Leads Pack
Read More
MGI In-Licenses Further Rights To Approved Cancer Drug Aloxi
Read More
Correction
Read More
Amgen Reports Phase III Data On Cinacalcet, Gets Priority Review
Read More
Other News To Note
Read More